Mr. Arvind Utchanah reports

KNIGHT ANNOUNCES CLOSING OF US$100 MILLION REVOLVING CREDIT FACILITY

Knight Therapeutics Inc. has closed the syndication of its $100-million (U.S.) secured revolving credit facility.

On June 17, 2025, Knight had announced that it had closed a $50-million (U.S.) revolving credit facility with National Bank of Canada (NBC) and initiated a syndication process to increase the size of the facility. As part of the syndication process, Knight has expanded its banking consortium to include three additional banks: Citibank N.A., Canadian Imperial Bank of Commerce and Toronto-Dominion Bank. The consortium now consists of four banks, with NBC as the lead arranger.

On Oct. 31, 2025, the revolving credit facility was increased to $100-million (U.S.) with an accordion feature for an additional $100-million (U.S.), subject to receipt of acceptance by the lenders. The credit facility is mainly intended to support the company's growth strategy and may also be used for working capital and other corporate purposes.

The credit facility has an initial maturity date of June 17, 2028, and can be extended annually by an additional one-year period. The credit facility can be drawn in U.S. dollars or Canadian dollars at the SOFR (secured overnight financing rate) or CORRA (Canadian overnight repo rate average) rate, plus an applicable margin of between 1.25 per cent and 2.75 per cent, depending on Knight's debt leverage. Knight will pay standby fees for the undisbursed portion of the credit facility. In addition, the credit facility includes certain customary financial and non-financial covenants that the company must maintain over the period of the agreement. In June, 2025, Knight withdrew $60-million (Canadian) from the credit facility to finance a portion of the Paladin acquisition.

"We are pleased to partner with NBC and the syndicate of lenders. This credit facility strengthens our relationship with four banks and doubles our borrowing capacity from $50-million (U.S.) to $100-million (U.S.), with an additional $100-million (U.S.) accordion feature. The financial flexibility of this partnership positions us well for acquisitions, as well as supports the growth of our business," said Arvind Utchanah, chief financial officer of Knight Therapeutics.

A copy of the amended and restated credit agreement will be available on SEDAR+.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.